Regulation - MannKind

Filter

Current filters:

MannKind

Popular Filters

MannKind’s diabetes drug Afrezza recommended by FDA advisory

02-04-2014

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationUSA

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

14-10-2013

MannKind has resubmitted its New Drug Application to the FDA for the marketing and sale of Afrezza Inhalation…

AfrezzaBiotechnologyDiabetesMannKindNorth AmericaRegulation

Positive results with MannKind's type 1 diabetes drug please investors

15-08-2013

There was good news for loss-making US drugmaker MannKind (Nasdaq: MNKD), when the company announced…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationResearch

Parexel

Parexel

Back to top